MannKind’s INHALE-1 Study: Pediatric Diabetes Breakthrough

MannKind Advances Pediatric Diabetes Treatment with INHALE-1 Study Completion

MannKind Corporation (NASDAQ: MNKD), a pioneering biopharmaceutical company, has recently achieved a significant milestone in the battle against diabetes by completing patient enrollment for its groundbreaking INHALE-1 study. This clinical trial is focused on evaluating the efficacy and safety of inhaled insulin Afrezza in children and adolescents suffering from type 1 or type 2 diabetes, marking a potential paradigm shift in diabetes management and treatment options for the pediatric population.